Nucleoside and pyrophosphate analogues are currently in use to treat infection with Human herpesvirus 1 (HSV-1). Both series of compounds exert their activity by inhibitionof the viral DNA polymerase either directly, or after anabolic pho~.J?horylation. As the X-ray structure of the viral-speciJ(t DNA polymerase is not known, it is difficult to dlf~lgn a nucleoside or non-nucleoside antiviral agent which specifically inhibits this enzyme. Therefore, alternative strategies have relied on extensive structure activity relationship studies of anti-HSV-1 agents in an endeavour to understand the essential structural requirements for activity and hence the design of drugs with increased selectivity. A virus-specific enzyme which plays a crucial role in the selective activation of nucleoside analogues is thymidine kinase. Present knowledge regarding the specificity of herpesvirus thymid,ine kinase for its 5-substituted-2'-deoxyuridine substrates is reviewed herein.
Introduction
Herpes-simplex virus (HSV) is a member of the alphaherpesvirinae and exists as two types: HSV type 1 (HSV-1) and HSV type 2 (HSV-2). Both viruses establish latent infections in nerve tissue. HSV is ubiquitous and infections in humans with HSV-1 leading to acute gingivostomatitis, herpes labialis or ocular disease are common. HSV-2 accounts for most cases of herpes genitalis.
When an otherwise healthy person is infected with HSV-1, the infection normally can be left untreated. However, special treatment might be required in immunologically deficient people (for example transplantation, cancer, or AIDS patients). Also HSV encephalitis, which contributes to mortality in neonates, needs antiviral treatment. A further reason for developing anti-HSV-1 agents is that HSV strains could develop resistance to the drug (Chatis and Crumpacker, 1992) . Resistance to antiherpes drugs is a serious clinical problem in immunocornpromised patients (Coen, 1991) .
New leads in drug discovery can be found by screening a large number of compounds. Once an active molecule is identified, it can be used as a model for chemical modifications. This strategy has proved successful in the discovery of drugs active against HSV-1. A more rational approach is based on a drug discovery cycle in which a new lead is identified by crystallographic methods and computer-assisted modelling. A significant amount of information is necessary, however, before a rational drug-design cycle can be started, i.e. kinetic properties, amino acid sequences and three-dimensional structures of the viral and human enzymes must be determined. As this information is not available for the HSV-specifiC enzymes, models based on known three-dimensional structures of related enzymes together with structural studies of known inhibitors are the sole resources for study of the interactions between the HSV enzymes and antiviral drugs. Such study can lead to more effective antivirals.
This paper will review the present knowledge regarding the specificity of HSV thymidine kinase (TK) for its 5-substituted 2'-deoxyuridine substrates.
Thymidine kinase
Thymidine kinase is a crucial enzyme in the salvage pathway of thymidine 5' -triphosphate which is the precursor of the thymidine incorporated into DNA.
The substrate specificity of humanTK (huTK) is essentially limited to thymidine. Viral TK differs in several aspects from huTK. The viral enzyme has a broader substrate specificity than the human enzyme and eve!""' L-thymidine (Spadari et al., 1992) and guanine nucleoside analogues (Le. acyclovir and ganciclovir) are accepted as substrates. Viral TKs also differ from the huTK in their diminished preference for specific phosphoryl donors (CTP as well as ATP are accepted [Cheng, 1976] ) and in their thymidine-5'-monophosphate kinase activity (Chen and Prusoff, 1978) .
Like HSV ribonucleotide reductase, the HSV TK is not essential for viral replication in cell culture. However, TK is 5-Substituted 2'-deoxyuridines as anti-HSV-1 agents 5-lodo-2' -deoxyuridine (Prusoff, 1959) was the first antiviral nucleoside to be discovered. In this series of 5-substituted 2'-deoxyuridines it was followed by the second generation antivirals: 5"trifluoromethyl-2'-deoxyuridine (Heidelberger, 1964) , 5-ethyl-2' -deoxyuridine (Swierkowski and Shugar, 1969) and 5-(E)-bromovinyl-2'deoxyuridine (De Clercq et aI., 1979a) . The antiviral activity of 5-trifluoromethyl-2'-deoxyuridine can be explained surprising that these molecules are either thymine or guanine analogues and one could speculate that they should bind at the same site as the normal substrates of the enzyme.
The TK from HSV-1 has been expressed in E. co/iwhich has permitted its isolation, purification, and crystallization (Enquist et aI., 1979; Wagner et a/., 1981; Sanderson et aI., 1988) . Also the human cytosol TK gene has been cloned and sequenced and its structure determined (Lin et aI., 1983; Bradshaw and Deininger, 1984; Lau and Kan, 1984; Flemington et el., 1987) . A theoretical three-dimensional model of the active sites of both HSV-1 TK and huTK has been developed (Folkers et aI., 1991) , based on a structural analysis of various kinases and a comparison with the known structure of reference enzymes. When comparing the sequence of the huTK and the TK of HSV-1, two regions seem to be important to give an explanation of their difference in substrate specificity: a phosphate binding site (GPXXXGKXT) and a binding site for the heterocyclic moiety of nucleosides (FDRH and flanking sequences for HSV-1 TK and FORK and flanking sequences for huTI<). The presence of an aspartate'F (D) permits the binding of guanine nucleosides by the herpes enzymes. Replacement of glutamine (0) in the human enzyme prevents this binding. The importance of aspartate 162 for the enzymatic activity was demonstrated by site-directed mutagenesis (Fetzer et a/., 1993) . It was speculated also that the difference in BrVdUrd sensitivity between HSV-1 and HSV-2 resides in an alanine (A)s erine (S)conversion at position 168 (PIAA168L and PIASL) (Folkers et a/., 1991) . The phosphate binding sites consist of a conserved region at the C-terminus with basic amino acids and a glycine-rich loop at the N-terminus. The thymidine binding site is located about 100 amino acids downstream from the phosphate binding loop. Apparently, this binding site determines the substrate specificity of the enzyme. Thymidine and ganciclovir were found to dock into the active site of both kinases. The 5-methyl group of thymidine points in the direction of the N-1 of ganciclovir. However, this study was not based on cocrystallization experiments, but on structural information Obtained from other nucleotide-binding enzymes i.e, adeñ ylate kinase (Folkers et st., 1991) .
CII,1 10 HQ important for the pathogenicity of the virus in humans (Coen, 1991) . Generally, TK-mutants have a reduced pathogenicity. The enzyme is also a key enzyme in the metabolic activation of antiviral agents. Modified nucleosides have a much higher affinity for HSV-1 TK than for cellular TK, such that preferential phosphorylation in virus-infected cells occurs. HSV TK is a potential target for drugs which might prevent reactivation of HSV when used prophylactically (Leib et aI., 1990) . Indeed, TK-viruses seem to be reactivation-incompetent. However, these TK-viruses can be reactivated upon a superinfection with a TK-competent virus (Coen et a/., 1989) . It has been demonstrated that a selective viral-TK inhibitor can either suppress or delay the reactivation (Nsiah et el., 1990; Kaufman et a/., 1991) . This effect is most pronounced when no cellular TK is present, i.e, in ocular recurrences of HSV-1 herpetic keratitis (Kaufman et aI., 1991) . In contrast, TK inhibitors block the activity of TK-dependent antiviral drugs (Klein and Czelusniak, 1990 ). Kaufman (Kaufman etel., 1991) concluded that inhibition of viral TK with a compound that has no direct effect on virus multiplication and cell metabolism can prevent recurrences of herpes. Such compounds can increase the efficacy of antiviral drugs which do not depend on phosphorylation by the viral-specific TK (i.e, phosphonoacetate) by slowing down the viral multiplication. Examples of potent TK inhibitors are 1-(2,5,6-trideoxy-I3-D-erythro-hex -5-ynofuranosyl) -5-methyluracil (5'ethynylthymidine) (Sharma and Bobek, 1978) , 9-{[(S)-2-(hydroxymethyl)cyclohexyl]methyl}guanine (L653180) (Ashton et aI., 1989) , N 2-phenyl-2'-deoxyguanosine (PhdG) (Focher et el., 1988) , and the 5'-[I3-(2,4-dichlorophenoxy) propionamido] derivative of 5' -amino-2' ,5'dideoxy-5-ethyluridine (Martin et el., 1989) (Fig. 1 ). It is not partly by the inhibition of thymidylate synthase after phosphorylation in the infected cells. Also the 5'-monophosphate of 5-ethynyl-2'-deoxyuridine is an inhibitor of thymidylate synthase (Rahim et sl., 1992) . Furthermore, other 2' -deoxyuridine analogues have the potential to become cytostatic by inhibiting thymidylate synthase, if their 5'-monophosphate derivatives can be generated in tumour cells. This might be achieved by transformation of the cells with the HSV-1 TK gene (Balzarini et sl., 1985) . A simpler and therapeutically more attainable method would be to synthesize a prod rug which delivers the nucleoside 5' -monophosphate into the cell. However, site-specific delivery could become a problem upon application of such a strategy.
The mode of antiviral action of 5-substituted-2'-deoxyuridine is essentially identical to that of 5-iodo-2' -deoxyuridine. This subject has been reviewed frequently in relation to 5-(E)-bromovinyl-2'-deoxyuridine as model compound (DeClercq, 1993) . Briefly, the modified nucleoside is phosphorylated preferentially by the HSV-1 encoded dThd/dCyd kinase to tt1@ 5'-monophosphate and the 5'-diphosphate; the latt~~~ls further phosphorylated to the 5'-triphosphate by a (cellular)kinase which, to date, remains unidentified. The triphosphates of these compounds act as competitive inhibitors to dTIP of the viral DNA polymerase, can function as substrates for this enzyme and can be incorporated into the DNA. Although this general mode of action can be used to explain the antiviral activity of most 5-substituted pyrimidine nucleosides, considerable differences exist between such compounds. As shown previously, thymidylate synthase can play an important role in the activity of a compound. Incorporation in DNA is an important mechanism for some compounds, such as BrVdUrd (Mancini et sl., 1983) , but this is not mandatory for the antiviral activity of other compounds as has been demonstrated for either carbocyclic BrVdUrd (Balzarini et sl., 1990 ) or BrVaraU (yokota et a/., 1989 .
A common characteristic for all5-substituted 2'-deoxynucleosides is that they have to be phosphorylated by the virus-specific kinase in infected cells. This means that a structure activity relationship study of 5-substituted-2'deoxyuridines should start by determining the relationship between the nucleoside's affinity for the viral-specific kinase and its physicochemical properties. Indeed, at least three (but usually more) enzymes are involved in the mode of action of these compounds. As the affinity of particular nucleosides and nucleotides could differ considerably for these enzymes, it makes little sense to try to correlate directly antiviral activity with structural data as shown below. This is most striking when it is recognised that the selectivity of some anti-HSV agents (e.g. 5methoxymethyl-2'-deoxyuridine) is due to their preferential phosphorylation by the viral TK, and not at the DNA 5-Substituted-2'-deoxyuridines as anti-HSV-1 agents 133 polymerase level (Aduma et el., 1992) ,while DNA polymerase is important in explaining the selectivity of other antiviral nucleosides.
A problem encountered when attempting to correlate meaningfully structure activity relationship data of 2'_ deoxyuridine derivatives with therapeutic potency is the discrepancy between in vitro and in vivo activities due to the action of several phosphorylases. Such is the case with uridine phosphorylase and thymidine phosphorylases. For example, UrdPase modulates the salvage pathway of pyrimidine nucleosides by their anabolic and catabolic conversions according to the following equilibrium (el Kouni eta/., 1988b):
Uridine phosphorylase (UrdPase) cleaves not only pyrimidine ribosides (except cytosine), but also the 2'_ and 5'-deoxyriboside nucleosides. This enzyme is responsible for the degradation of the antiviral5-substituted 2' -deoxyuridine. For example, BvUdUrd is rendered inactive in vivo by rapid conversion to bromovinyluracil (De Clercq and Walker, 1986; Desgranges et aI., 1983) .Therefore, it could be beneficial to use UrdPase inhibitors in combination with the 5-substituted-2'-deoxyuridines in order to inhibit the degradation of the active pyrimidine nucleoside. Several UrdPase inhibitors have been reported (Baker and Kelly, 1970; Woodman et a/., 1980; Niedzwicki et aI., 1983; Chu et aI., 1984; Lin and Liu, 1985; Siegel and Lin, 1985; Veres et sl., 1985; Park et aI., 1986; Drabikowska et aI., 1987; Naguib et a/., 1987; Chu et a/., 1988; el Kouni et a/., 1988a el Kouni et a/., , 1988b Grancharov et aI., 1991). It may also be possible to circumvent enzymatic degradation by synthesizing phosphorylase-stable compounds. Such compounds were obtained in the past by modification of either the base (Le. cytosine nucleosides) or sugar (i.e, arabinofuranosyl nucleosides [Kumagai et si., 1989] , 2'-f1uorinated nucleosides [Iwashina et el., 1988] , 4'-thionucleosides [Dyson et aI., 1991] ). With the exception of 2'-fluorinated compounds, these modifications generally gave less potent compounds. Therefore, it would be desirable to have a 2'-deoxyuridine derivative with a 5-substituent which confers both high activity and phosphorylase stability. In this context it must be noted that, in contrast with BVdUrd, the recently discovered 5-thienyl-and 5-furanyl 2'-deoxynucleosides are poor substrates for dThd phosphorylase (C. Bohman et aI., 1994) , and that, because of their susceptibility to phosphorylase, the application of 5-substituted 2'-deoxyuridines usually is restricted to herpes eye infections (approximately 90% of ocular herpes infections are caused by HSV-1).
It is important that a structure activity relationship study be restricted to one series of modifications. Modifications at sites other than the 5-position give rise to compounds for which the mode of action can differ considerably. This can be demonstrated by studying the antiviral activity of 5-substituted 2'-deoxyuridine derivatives with additional modifications in the base moiety. 2'-Deoxycytidine analogues are an interesting example. 2'-Deoxycytidine analogues are generally less active in vitro than their 2' -deoxyuridine counterparts (DeClercq and Rosenwirth, 1985; Jones et aI., 1988; Kumar et al., 1990a) .On the other hand, 5-substituted-2'-deoxycytidines often are more selective inhibitors of HSV than the corresponding 2'deoxyuridine derivatives (Aduma et aI., 1991 (Aduma et aI., , 1992 .Thus, although the potency of the deoxycytosine analogues (Jones et aI., 1988; Kumar et aI., 1990a ) (CIVdCyd, BrVdCyd) ( Fig.2 ) in vitro generally is less than the potency of the deoxyuridine analogues (CIVdUrd, BVdUrd), it is possible that related cytosine analogues can be better antivirals. In this case, alternative metabolic pathways must be considered to account for such phenomena.
2'-Deoxycytidine analogues are phosphorylated efficiently by the pyrimidine nucleoside kinase of HSV (Aduma et al., 1991) and also can be deaminated to give the corresponding 2'-deoxyuridines. Furthermore, 2'_ deoxycytidine analogues are metabolically more stable against phosphorylase hydrolysis. Mammalian cells do not possess enzymes that cleave the glycosidic bond of cytosine nucleosides (de Verdier and Potter, 1960) . In contrast, 2' -deoxyuridine analogues are catabolized rapidly. Therefore, the potency of 2' -deoxycytidines (Aduma et aI., 1990a (Aduma et aI., , 1990b against HSV-1 increases in the presence of tetrahydrodeoxyuridine which is a dCyd/ dCMP deaminase inhibitor. In these circumstances, 2'deoxycytidine analogues are catabolized neither by deaminases nor by phosphorylases (Aduma et al., 1990a) ,and they can be anabolized, unimpeded, in infected cells by the dCyd kinase/dCMP kinase pathway to their triphosphate derivatives. In some cases, the 5-substituted 2'-deoxycytidine triphosphate is utilized preferentially over the natural substrate dCTP by HSV DNA polymerase, while the human DNA polymerase a utilizes the 5-substituted 2' -deoxycytidine triphosphate to about the same extent as dCTP. This is demonstrated for 5-methoxymethyl-2'-deoxycytidine triphosphate which also is a better inhibitor of the viral enzyme than 5-methoxymethyl-2'deoxyuridine triphosphate (Aduma et al., 1991 (Aduma et al., , 1992 .The viral enzyme discriminates less between 5-monomethoxy-2'-deoxyuridine triphosphate and dTIP.
Moreover, it was suggested that the higher HSV-1 selectivity of some 2'-deoxycytidine analogues could be explained partly by the capacity of such compounds to act Table 1 . 2' -Deoxyuridine derivatives with a saturated 5-substituent and endowed with anti-HSV-1 activity.
Substituent

HSV-1 activity' Substituent
HSV-1 activity'
-CH 2-CHa (De Clercq and Shugar, 1975) 0.9 (a) (1) -CH2-S-CHa -CH(CH a )2 (De Clercq, 1980) 4 (a) (1) -CH2S02-CHa -CH 2-CH2-CH2-CHa (Goodchild et al., 1983) 10 (d) (5) -CH20H (De Clercq, 1980 ) -CH 2-CH2-F (Griengl et al., 1987) 0.1 (a) (1) -CH2-O-CHa (Gupta et al., 1987) -CH 2-CH2-CI (Griengl et et., 1985) 0.3 (c) (4) -CH(OCHa)-CH2-Br (Kumar et al., 1989) -CH 2-CH2-Br (Griengl et al., 1985) 3 (Griengl et al., 1985) 1 (c) (4) -CH(OH)-CH2-CI (Kumar et et., 1989) -CH 2-CH2-CH2-CI (Griengl et al., 1985) 0.3 (c) (4) -CH(OH)-CH(I)-COOEt (Kumar et el., 1989) F 4 F (Tandon et ei., 1992) 5 (b) (2) -CH(OH)-CH(Br)-COOEt (Kumar et al., 1989) * IC 50 : concentration (flog rnr ') required to reduce virus-induced cytopathogenicity by 50%. 6 (a)(1) as substrates for DNA methyltransferase after their incorporation into DNA, for example, 5-trifluoromethyl-2'deoxycytidine ( Fig. 2) , an active HSV-1 agent, can be incorporated selectively into the DNA of HSV-infected cells. This stimulates the methylation of the DNA. As there is a correlation between hypermethylation and genetic down-regulation, agents which can affect selectively the methylation status of the virus-infected cells may decrease virus replication (Barletta and Greer, 1992) . For all these reasons, 2' -deoxycytidine and 2'-deoxyuridine compounds should be considered separately when working out a structure activity study.
A further criterion which adds to the validity of a structure activity study is the selection of conformationally stable compounds. Therefore, the compounds identified in Table 1 which have a flexible 5-substituent provide less information than those in either Table 2 or Fig. 3 . Two extensive structure activity relationship studies on 5-substituted 2'-deoxyuridine derivatives have been published previously. After synthesizing several 5-unsaturated derivatives, Goodchild et al. (1983) concluded that, for anti-HSV-1 activity, the 5-substituent should be conjugated, not larger than 4 carbons, hydrophobic, inductive and unbranched. In addition, they indicated that cytosines are less active than uracils. Although this study did not relate activity to any physicochemical parameter, the hypothesis still holds for the group of compounds depicted in Table 2 . A linear free energy-relationship study was undertaken (Chang and Mertes, 1987) between physical and spectral data of 5-phenyl substituted 2,4-dioxopyrimidine nucleosides with Hammett (J constants. The requirement of the 5-substituent for active-site binding of thymidylate synthase also was investigated (Chang et aI., 1988) . These studies revealed that higher electron densities at the oxygen atoms correlate with an increase in binding, and that the presence of hydrophobic substituents enhances affinity. However, the study by Chang and Mertes is not related to antiviral activity.
Biological data resulting from in vitro and in vivo screening are the final results of several processes occurring in the cell. These data depend on the experimental circumstances. Such factors are. considerably more significant than experimental error in analytical data. Therefore, it is very difficult to compare and interpret accurately data from different laboratories. The 5-substituted 2'-deoxy-nucleosides in Tables 1 and 2 and Fig. 3 are arranged into three groups depending on their structural characteristics. The biological activities are taken from Table 2 . 2'-Deoxyuridine derivatives with an unsaturated 5-substituent and endowed with antt-Hsv-t activity.
-p----Substituent -CH=CH 2 (De Clercq et al., 1979a) -CH=CH-CI -CH=CH-Br (De Clercq et al., 1979a) -CH=CH-I (De Clercq et al., 1979a ) -CH=CH-CF 3 (Bergstrom et al., 1984 ) -CH=CH-F (Reefschliiger et al., 1984 -CH=CH-CH 3 (Bergstrom et al., 1984) -CH=CF2 (Bobek et al., 1987a) -CF=CF 2 (Herdewijn et al., 1992) -CF=CFCI (Coe et al., 1982) -CH=CH-COOCH 3 (Griengl et el., 1985) -CCI=CH2 (De Clercq et al., 1979a) -CH=CH-CH2-CH3 (Goodchild et al., 1983) -CH 2-CH=CH-CH3 (Goodchild et al., 1983) HSV-1 activity' 0.04 (a) (1) 0.02 (a)(1) 0.Q1 (a) (1) 0.01 (a) (1) 0.03 (a)(1) (De Clercq at al., 1979a) -CH='"C-CH3 -C='"C-CH2-CH3 -C='"C-CH2-O-CH3 ) -C='"C-C(CH3la ) -C='"C-CH2-CH 2-CH 3 ) -C='"C-CH=CH2 -CH=O (Park et al., 1980) -CH=N-OH (Park et al., 1980) -CH=CBr2 (Goodchild et al., 1983) -CH=CH-S-CH3 (Goodchild et al., 1983 ) -C(CH 3)=CH-Br (Goodchild et aI., 1983) -CH =C(Br)-CH3 (Goodchild et al., 1983) HSV-1 activity'
• ICso: concentration (fL9 rnr') required to reduce virus-induced cytopathogenicity by 50%. Tables 1 and 2 are restricted to those endowed with anti-HSV-1 activity. Fig. 3 gives a survey of the 2'-deoxyuridines with a 5-heteroaryl substituent synthesized to date. Their anti-HSV-1 activity is shown in Table 3 .
Synthesis of 5-substituted 2'-deoxyuridines and 5substituted 2'-deoxycytidines
2'-Deoxynucleosides with a 5-substituted pyrimidine base moiety have been synthesized, most efficiently, starting from 5-iodo-2'-deoxyuridine (first method). Synthesis by a sugar-base condensation reaction of a modified pyrimidine with activated 2'-deoxyribose (second method) was used prior to the availability of the Pd-catalysed cross-coupling reaction (Barr et al., 1981; Budesinsky et a/., 1982) .As an example, 5-substituted-2'deoxycytidines were obtained by condensation of 5-substituted 2,4-bis-O,N-trimethylsilylcytosine with 2-deoxy-3,5-di-O-p-toluoyl-D-erythropentosyl chloride followed by separation of the ex and 13 anomers by reversed-phase HPLC (Fig. 4) . For the synthesis of 5-(3-n-hexyl-2-thienyl) dUrd, 5-(3-methyl-2-thienyl)dUrd, 5-(2-thienyl)dCyd and 5-cyclopropyl-dCyd, copper(l)iodide was added to obtain higher yields of the 13 anomer (Peters et al., 1992) .
The decision to synthesize cytosine analogues by a sugar-base coupling strategy was based on the observation that the preparation of 3' ,5'-di-O-protected 5-(2-thienyl)-2'-deoxycytidine, 5-(2-thiazol)-2' -deoxycytidine and 5-(5-phenyl-2-thienyl)-2' -deoxycytidine from the corresponding 3' ,5'-di-O-protected 5-heteroaryl-2'-deoxyuridines (Peters et al., 1991) proved unsuccessful. This failure probably was the result of steric hindrance. In contrast, other authors described successful results for this type of conversion (Wigerinck et el., 1991a) .
A third method for the synthesis of these nucleoside analogues involves a stepwise construction of the 5-substituent starting from simple starting materials. Although this method is less attractive than the direct coupling reaction, it can be used when the Pd-catalysed reaction ,--I fails and good yields of the final products have been reported (Wigerinck et aI., 1991b (Wigerinck et aI., , 1993 Whale et el., 1992) . The synthesis of several 5-substituted 2'-deoxyuridine nucleosides (Table 4) has been achieved using a methodology based on the original Heck reaction (Heck, 1968) which involves the Pd-catalysed reaction (e.g. using Li 2PdCI4 [Bergstrom and Ruth, 1976; Bergstrom and Ogawa, 1978; Goodchild et aI., 1983] either alone or in conjunction with CuCI 2, as in later reports [Goodchild et aI., 1983] ) of conjugated alkenes (e.g. methylacrylate) with 5-mercurated-2'-deoxyuridine (Table 4 , Entry 1).
The Pd-catalysed reaction conditions used for the synthesis of 5-alkenyl~substituted nucleosides were applied also to 5-iodinated 2' -deoxyuridines in the presence of Pd(OAcb,EtsN, <!>sP (Bergstrom and Ogawa, 1978; Goodchild et aI., 1983) (Table 4 , Entry 2). This is the method of choice in the author's laboratory (Herdewijn et a/.,1985) .
Terminal alkynes are coupled to the 5-position of pyrimidine nucleosides in a similar manner. A mixture of either Pd(<!>sP)4,Cul,Et sN (Goodchild et a/., 1983) or (<!>sPbPdCI 2,Cul,EtsN Bobek et a/., 1987b) is used most often (Table 4 , Entry 3).
The reaction of organometallic reagents, like alkynylzinc in the presence of (<!>sPbPdCb (Vincent et aI., 1985a) and alkenylzirconium in the presence of (<!>CNbPdCI 2 (Vincent et el., 1985b) , on 5-iodinated nucleosides is less attractive because of the necessity to synthesize the organometallic starting materials. A water-soluble Pd(O) complex (Pd[<!>2P[m(C6H4SOsNa)b was used to catalyse the reaction between 5-iodo-2' -deoxyuridine and propargyltrifluoroacetamide (Casalnuovo and Calabrese, 1990) .
The Li 2PdCl4-catalysed coupling reaction of either 5chloromercuri-2' -deoxyuridine with iodobenzene or 1iodo-3-nitrobenzene is a low yielding reaction (Bigge and Mertes, 1981) . The Pd(O) [Pd(<!>sP)4]-catalysed biaryl coupling is more efficient and generally yields between 40 and 60% are obtained (Chang and Mertes, 1987 ) (Table·4, Entry 4). Other workers have applied this type of reaction to cytosine nucleosides. However, the Pd-catalysed cross-coupling of halogenated aryls and heteroaryls with unprotected 5-acetoxymercuri-2'-deoxycytidine in the presence of either Li 2PdCI4 or a mixture of LbPdCI 4,CuCI2 also is low yielding (Hassan, 1991c) ; the reaction was not repeated using Pd(<!>SP)4 as catalyst.
Palladium-catalyst biaryl-coupling reactions which involve the treatment of 5-iodinated nucleosides with the zinc chloride salt of either aromatic or heteroaromatic compounds have been described also using either di(triphenylphosphine)dichloropalladium (Vincent et a/., 1981) , or tetrakis(triphenylphosphine)palladium (AI-Razzak et aI., 1987; Wigerinck et aI., 1991a) as catalyst (Table4, Entry 5). In the approach of Mertes (AI-Razzak et aI., 1987) a Pd-nucleoside complex was formed first and was followed by addition of the zinc chloride salt. Although reactions with a variety of different compounds are described in this literature, the methods using (<!>sP)4Pd seem to produce the highest yields.
A photochemical coupling reaction (irradiation at 254 nm) of the trimethylsilyl derivative of 5-iodo-2' -deoxyuridine with either benzene or 1,4-dimethoxybenzene yielded 5-phenyl 2'-deoxyuridine and 5-(2,5-dimethoxyphenyl)-2' -deoxyuridine in 18% and 32 % respectively (Bigge and Mertes, 1981;  Table 4 , Entry 6). Similar reactions using methylacrylate and acrylonitrile also were low yielding (12% and 41% yields respectively; Hassan, 1986) . The aromatic photosubstitution of trimethylsilylated 5-iodo-2'-deoxyuridine and 2,3-dimethyl-1 ,4-dimethoxybenzene in acetonitrile at 310 nm gave a 15% yield of the photocoupled compound (AI-Razzak et aI., 1987) . Better yields (25%) were obtained by photolysis at 254 nm with 2,3,5-trimethyl-1 ,4-dimethoxybenzene. However, problems with regioselectivity were encountered when the same method was used for the synthesis of naphthyl derivatives (AI-Razzak et el., 1987) . Photoirradiation of a , deoxygenated solution of the trimethylsilyl derivative of 5-iodo-2' -deoxycytidine with alkenes, aromatic and heteroaromatic ring structures has been described for the synthesis of 5-substituted 2'-deoxycytidines (Hassan, 1991b (Hassan, , 1991d : the yields ranged from 25% to 40%.
The photochemical approach used to synthesize 5-substituted 2'-deoxypyrimidine nucleosides also has been carried out directly on 2'-deoxyuridine, 2'-deoxycytidine and their trimethylsilylated derivatives (Table 4, Entry 7) respectively. Photolysis of a mixture of 2-chloro-1,4dimethoxybenzene and the trimethylsilyl derivative of 2' -deoxyuridine gave 5-(2,5-dimethoxyphenyl)-2' -deoxyuridine (AI-Razzak et aI., 1983) . Only 4% yield of the coupling product was obtained by irradiation of a mixture of protected 2' -deoxyuridine and 2-bromo-3-methyl-1 ,4dimethoxynaphthalene at 310nm (AI-Razzak et al., 1987) . Photoirradiation of cytosine nucleosides in the presence of either diverse alkenes or halogenated alkanes afforded 2' -deoxycytidine derivatives having a 5-unsaturated substituent in 20-30% yield (Hassan, 1991d . When silylated 2' -deoxycytidine was irradiated in the presence of halogenated heteroaromatics, yields of 10-30% of 5-heteroaromatic-substituted 2' -deoxycytidines were isolated (Hassan, 1991b) . The regioselectivity of the addition of the aryl (heteroaryl)radical can be explained by the higher electron density on carbon-S, Because of the relatively low yields generally observed for the photochemical reactions, this approach (Table 4 , Entries 6 and 7) is less attractive for preparative purposes.
Reaction of 3' ,5' -O-di-silylated 5-iodo-2' -deoxyuridine with phenylboronic acid, along with various derivatives restricted to those possessing substituents with electron- Table 4 . Palladium-catalysed cross-coupling reactions used for the synthesis of 5-substltuted-2'-deoxyuridines.
Pd2dbas: tris(dibenzylidene-acetonyl)bispalladium.
* Also 5-0-triflates have been used as starting materials instead of 5-iodinated nucieosides (Crisp and Flynn, 1990; Flynn et al., 1991 Goodchild et al. (1983) Bergstrom and Ogawa (1978) Goodchild et al. (1983) Robins and Bigge and Mertes (1981) Mertes (1984, 1987) Bigge and Mertes (1981) Hassan (1985 Hassan ( ,1986 AI-Razzak et al. (1983) Hassan (1985, 1991c) Yamamoto et al. (1989) Crisp and Macolino (1990) Crisp (1989) Herdewijn et al. (1992) Herdewijn et al. (1991) Farinaand Hauck ( ...... co CO donating groups (e.g. 4-methoxyphenylboronic acid and 4-dimethylaminophenylboronic acid), in the presence of tetrakis(triphenylphosphine)palladium in toluene/aqueous Na2C03 gave 5-aryl substituted 2'-deoxyuridines in 35-55% yield (Crisp and Macolino, 1990; Flynn et aI., 1991) (Table 4 , Entry 8). Boron-10 containing nucleosides were synthesized as potential antitumour agents by reactions involving Pd-catalysed coupling. Heating 2,2dimethylpropane-1 ,3-diol protected 4-tributyltinphenylboronic acid in toluene in the presence of Pd(<P3P)4 and silylated 5-bromouridine gave the 5-arylboronic acid derivative (Yamamoto et aI., 1989) . This result indicates that the Pd-catalysed reaction proceeds chemoselectively to involve the carbon-tin bond rather than the carbon-boron bond. Apparently, organotin compounds are better reagents than organoboron compounds for carrying out these coupling reactions.
Reaction of 3' ,5'-di-O-toluoyl-5-iodo-2'-deoxyuridine with alkenylstannanes in acetonitrile in the presence of di(triphenylphosphine)dichloropalladium gave 5-alkenyl-2'-deoxyuridine in about 80% yield (Crisp, 1989 ; Table 4 , Entry 9). The rate of the reaction can be enhanced considerably (1 0 2-1 03-fold) by using either triphenylarsine or tri(2-furyl)phosphine instead of triphenylphosphine (Farina and Hauck, 1991; Farina and Krishnan, 1991) . High yields were obtained by reacting 5-iodouridines with vinyltributyltin in the presence of tri(2-furyl)phosphine and the air-stable tris(dibenzylidene-acetonyl)bispalladium in N-methylpyrrolidinone (NMP) (Farina and Hauck, 1991) . Symmetrical tetraorganotin reagents have been used to synthesize 5-vinyl-2'-deoxyuridine, thymidine and 5phenyl-2'-deoxyuridine (Herdewijn et aI., 1991) . These reactions were conducted in hexamethylphosphoric triamide using tetrakis(triphenylphosphine) Pd as catalyst. Normally, transient acetylation (acetone pyridine) is used instead of toluoylation. Lower yields (20%) were experienced during efforts to synthesize 5-perfluorovinyl-2'deoxyuridine (Herdewijn et aI., 1992) using a mixture of <p3P,Et3N,Pd(OAcb as a catalyst; the reactions were conducted in NMP on tritoluoylated 5-iodo-2'-deoxyuridine using (tetrakis)perfluorovinyltin.
Cross-coupling of 3' ,5'-di-O-acetyl-5-iodo-2'-deoxyuridine with heteroaryltrimethylstannanes in the presence of di(triphenylphosphine)dichloropalladium in tetrahydrofuran furnished a series of 5-heteroaryl substituted 2'deoxynucleosides in moderate yields (25-60%; Table 4 , Entry 10; Peters et aI., 1991) . Similar yields (60--70%) of 5-heteroaryl substituted 2'-deoxyuridine derivatives were obtained by reaction of unprotected 5-iodo-2'-deoxyuridine with heteroarylstannanes in tetrahydrofuran using the same catalyst (Hassan, 1991a) . The reaction of arylstannanes, substituted with electron withdrawing groups (i.e. substituents which gave no reaction with the boronic acid reagents), with 3',5'-di-O-silylated 5-iodo-2'-deoxyurid-ine in dioxan (75%) and in the presence of Pd(<P3P)4 gave the corresponding 5-aryl substituted derivatives in 40--50% yield (Crisp and Macolino, 1990; Flynn et aI., 1991) .
Coupling reactions of either protected or unprotected 5-iodo-2'-deoxyuridine with 2-(trialkylstannyl)thiophene and 2-(trialkylstannyl) furan respectively were investigated by Wigerinck et al. (Wigerinck et aI., 1991a) .They obtained good results with either PdCb(<P3Pb as catalyst in a coordinating solvent (THF, dioxane) or Pd(<P3P)4 in a non-coordinating solvent. Also, the mixture Pd(OAcb<p3-P,Et 3N in dioxan proved to be an effective catalyst in these reactions (Maggiora et aI., 1983; Wigerinck et aI., 1991a) . Generally, yields above 70% were obtained.
Efforts to prepare 5-heteroaromatic substituted 2'deoxyuridine by an 'inverse' Pd-catalysed coupling were limited. Protected 5-trimethylstannyl-2'-deoxyuridine was prepared by reacting 5-iodo-2'-deoxyuridine with hexamethylditin and (<P3P)4Pd in ethylacetate (Wigerinck et aI., 1993) . This material was used to synthesize 5-(5iodothien-2-yl)-2'-deoxyuridine and 5-phenyl-2'-deoxyuridine.
5-0-Triflates also are efficient coupling reagents. Reaction of either vinylstannanes or arylstannanes, possessing either electron donating or electron withdrawing substituents (although the presence of electron withdrawing substituents enhances the rate and gives higher isolated yields) with protected 5-(trifluoromethanesulphonyloxy)uridine in dioxan and catalysed by Pd(<P3P)4 and LiCI (a polymerization inhibitor may also be added) gave the 5-substituted pyrimidine nucleosides (Crisp and Flynn, 1990; Flynn et al., 1991) . Also, the reverse reaction using for example 2-propenyl triflate, uridine and Pd(<P3P)4, LiCI has been described (Hassan, 1991t) . The disadvantage of the 5-0-triflate method is that it requires the additional operation of preparing the triflatedstarting material from 5-hydroxypyrimidine nucleosides.
Structure activity relationship of 5-heteroaryl sUbstituted nucleosides
The 5-heteroaromatic substituted 2'-deoxynucleosides can be divided into two groups ( Table 3 ).
The first group of very potent compounds involves 5-(thien-2-yl)-2'-deoxyuridine and 5-(furan-2-yl)-2'-deoxyuridine as lead structures. The antiviral activity of these compounds is retained when the heterocyclic ring is connected via its 3-position. When a halogeno substituent is introduced in the 5-position of the thiophene substituent, the activity against HSV-1 increases. However, this is not so pronounced when a halogen substituent is introduced in the furan ring. Clearly, there is a difference between both groups of compounds. The presence of a saturated or unsaturated alkyl group in the same position of the thiophene ring does not improve the anti-HSV-1 activity.
Compounds in the second group are those with a low anti-HSV-1 activity represented by the isoxazole, thiazole, phenyl and bromoisoxazole ring structures. 5-(Bromothien-2-yl)-2'-deoxyuridine has been tested in vivo (Wigerinck et al., 1993) .The compound is as effective as BrVdUrd in the topical treatment of HSV-1 keratitis in rabbits. The arabinofuranosyl analogue has been tested in mice after intraperitoneal infection with HSV-1 (KOS) (Wigerinck et aI., 1993) and proved not to be very efficient. However, it should be noted that the arabinofuranosyl compound is less active than the deoxyuridine analogue. Moreover, the antiviral efficacy in mice clearly is affected by the degree of virulence of the HSV-1 strain used in the test. It has demonstrated that Brovavir (BrVaraU) is efficient in a HSV-1 strain (WT-SI) of moderate virulence, has a modest effect in models with virulent strain of HSV-1 (VR-3) , and is not effective in mice infected i.p. with a highly virulent strain of HSV-1 (KOS) (Machida and Takezawa, 1990) . It is, however, veryo,;gifficult to interpret in vivo studies when no pharmacokinelt6s studies have been carried out.
As the first step in the metabolic activation of these nucleosides isthe phosphorylation by the HSV-1 TKtothe 5'-monophosphate, there may be a relationship between the enzymatic affinity and the HSV-1 activity. The affinity of the compounds for HSV-1 TK has been evaluated by C. Bohman et al. (Bohman et aI., personal communication) (IC 5 0 values are given in Table 3) .
From these data, it is clear that the compounds are less well phosphorylated by HSV-1 TK than either thymidine or BrVdUrd. The compounds with low antiviral activity also are badly phosphorylated by HSV-1 TK. However, the opposite is not always the case and the relationship between HSV-1 activity and enzymatic affinity is not straightforward. Generally, the compounds with high anti-HSV-1 activity show high affinity for HSV-1 TK except for the halogenated furan analogues. 5-(Thien-2-yl)-2'deoxyuridine and its chlorinated and brominated analogues are equally well phosphorylated. The latter compounds, however, are ten times more active than anti-HSV-1 agents. The affinity for the viral TK of 5-(chlorofuran-2-yl)-2'-deoxyuridine and 5-(bromofuran-2yl)-2' -deoxyuridine is 10-20 times lower than the affinity of 5-(furan-2-yl)-2'-deoxyuridine and 5-(thien-2-yl)-2'deoxyuridine. However, all these compounds demonstrate about the same antiviral activity. Although, clearly, 5'-0-phosphorylation is necessary for antiviral activity, it is not the decisive factor in determining the potency of a compound. It can be assumed that the effect of the triphosphate metabolite at the level of the HSV-1 DNA polymerase is at least as important in explaining the potency of a compound. The structure activity relation- ship in relation to each enzyme clearly is different. Therefore, data on the inhibition of DNA polymerase catalysis of the triphosphates of these compounds are necessary to give a fuller explanation for their relative potency.
Finally, the author tried to correlate biological activity with structural data. An X-ray study of the 3' ,5' -O-diacyl derivative of 5-bromovinyl-2' -deoxyuridine (Parkanyi et aI., 1987) revealed that the bromovinyl function is quasicoplanar with the pyridimine base and an intramolecular hydrogen bond existing between the oxygen atom of the C-4 carbonyl group and the u-hydrogen atom of the bromovinyl group (Fig. 5 ).
In order to be able to correlate biological data with structural data, an X-ray crystallographic study was undertaken of 5-(furan-2-yl)-2' -deoxyuridine, 5-(thien-2yl)-2' -deoxyuridine, 5-(furan-3-yl)-2'-deoxyuridine, 5-(thien-3-yl)-2' -deoxyuridine, 5-(chlorothien-2-yl)-2'deoxyuridine, 5-(bromothien-2-yl)-2'-deoxyuridine, 5-(bromo-furan-2-yl)-2'-deoxyuridine, 5-(bromoisoxazolyl)-2'-deoxyuridine and 5-(isoxazolyl)-2' -deoxyuridine (Evrard, 1992; Creuven, 1993 ).
X-ray structural analysis revealed that all compounds have a quasi-coplanar geometry between the 5-membered heterocyclic ring and the uracil base (Fig. 6) . Intramolecular interaction stabilizes the formation of pseudo five-or six-membered rings. With the 2-thienyl compounds, coplanarity is stabilized by an interaction between the carbonyl-group in 4-position of the uracil base and the sulphur atom of the thiophene ring ( Fig. 6 , structure A).The average distance between these atoms is smaller than the sum of their van der Waals radii. The X-ray structure (Fig. 6B) of the 3-thienyl and 3-furfuryl compound is stabilized by an intramolecular contact between 0 4 and HC(2'l The structures of the 2-furanyl analogue (Fig. 6C )and isoxazole analogue (Fig.60) clearly are different. While in structure A a pseudo five-membered ring is formed and structure B is stabilized by the formation of a six-membered pseudocycle, structures C and 0 can be distinguished by the formation of both a pseudo five-membered and a pseudo six-membered ring. Both rings are stabilized by pseudo hydrogen bonds. A pseudo vier et al., 1994) . Results from this work showed clear differences between the 2'-deoxyuridines that are good substrates for the HSV-1 TK and those that are poor substrates. The molecular electrostatic potential isocontour maps in the plane of the molecules show negative (attractive forces) potential levels at the carbonyl group of the uracil base, the chloro-atorn of the chlorothienyl group, the oxygen atom of the furanyl group and the Q-N bond of the isoxazolyl group. At a distance of 1.75A above the ring, however, a large negative (attractive) region is located above the 5-membered heterocycle for both active compounds (chlorothienyl and furanyl) and a large positive (repulsive) region above the uracil ring. With the inactive isoxazolyl compound the positive (repulsive) region is situated above the whole molecule (both uracil and isoxazolyl rings) except for the nitrogen atom of the isoxazolyl ring which has a negative region above it. Thus, there is a clear difference between molecular electrostatic energy maps of the active compounds and those of the inactive compounds (i.e. a difference between molecules which are good substrates for the HSV-1 TK and those which are poor substrates). This hypothesis was confirmed by calculating the molecular electrostatic potential maps for 5-(bromofuran-2-yl)-2'-deoxyuridine and 5-(bromoisoxazol-5-yl)-2'-deoxyuridine.
Conclusion
Until viral-specific enzymes together with their human counterparts are available in crystalline form and hence are characterized fully, models based on either known three-dimensional structures of related enzymes together with structural studies of known inhibitors are the sale resources to study the dynamic interactions between the HSV enzymes and antiviral drugs. The study of the physicochemical characteristics of the 5-substituent of 5-substituted-2'-deoxyuridine derivatives has given greater insight into the structural requirements of these nucleoside analogues for acceptance as substrates for TK.
The literature reviewed in this text supports the hypothesis that the electronic characteristics of the 5-substituent of 2'-deoxyuridine derivative are important for the interaction with the TK. All compounds which are good substrates for this enzyme demonstrate a large attractive region 1.75 A above the five-membered heterocycle whi~h seems to be important for the binding to the enzyme. Moreover, a similar profile is found for BrVdUrd: an attractive region above the bromovinyl group and a repulsive region localized above the uracil ring (A.Olivier et al., Facultes universitaires Notre-Dame de Ta Paix, Namur, Belgium, personal communication). These studies are an important contribution to the development process of new selective antivirals. hydrogen bond is formed between the oxygen of the furane (and isoxazole) ring and the H-6 atom, and a second pseudo hydrogen bond is formed between H-3" (or H-4'1 and the carbonyl group in the 4-position of the uracil base. This means that all compounds with a 5-thien-2-yl substituent can be superimposed while compounds with a 5-furan-2-yl substituent and 5-isoxazol-5-yl substituent clearly are different from those with a 5-thienyl substituent, The oxygen atom of the furanyl ring and the isoxazolyl ring is pointed in the opposite direction to that of the sulphur atom of the thienyl ring. 5-Furanyl (active) and 5-isoxazolyl (inactive) compounds can be distinguished by a different charge delocalization: a more pronounced negative charge is associated with position 4" of the isoxazolyl ring than that with position 3" of the furanyl ring and a less negative charge is associated with the isoxazolyl oxygen atom than with the furanoyl oxygen atom. The polarity between C(4'1 = C(5'1 in the furanyl ring is the inverse of that in the isoxazolyl ring C(3') = N (Evrard, 1992; Creuven, 1993) . Such structural differences could explain the difference in anti-HSV-activity and enzymatic affinity of this series of molecules. However, before any definitive conclusions can be drawn, this study was elaborated with theoretical calculations.
To compare the structures more thoroughly, theoretical calculations were carried out on two active compounds, namely 5-(furan-2-yl)-2'-deoxyuridine and 5-(5-chlorothien-2-yl)-2'-deoxyuridine and on one inactive compound, namely 5-(isoxazolyl)-2'-deoxyuridine (A. Oli-
